MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Ovid therapeutics Inc

Fechado

SetorSaúde

0.33 10

Visão Geral

Variação de preço das ações

24h

Atual

Mín

0.3

Máximo

0.33

Indicadores-chave

By Trading Economics

Rendimento

4.8M

-9.3M

Vendas

-97K

76K

EPS

-0.13

Margem de lucro

-12,175

Funcionários

23

EBITDA

2.5M

-11M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+948.39% upside

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-12M

25M

Abertura anterior

-9.67

Fecho anterior

0.33

Sentimento de Notícias

By Acuity

50%

50%

180 / 386 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

Ovid therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

17 de jun. de 2024, 13:34 UTC

Grandes Movimentos do Mercado

Ovid Therapeutics Shares Slide Premarket After Takeda's Soticlestat Setback

Comparação entre Pares

Variação de preço

Ovid therapeutics Inc Previsão

Preço-alvo

By TipRanks

948.39% parte superior

Previsão para 12 meses

Média 3.25 USD  948.39%

Máximo 4 USD

Mínimo 2 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Ovid therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

5 ratings

5

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

0.3077 / 0.4257Suporte e Resistência

Curto Prazo

Strong Bearish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Weak Bearish Evidence

Sentimento

By Acuity

180 / 386 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.